Your browser doesn't support javascript.
loading
Network effects of Stanford Neuromodulation Therapy (SNT) in treatment-resistant major depressive disorder: a randomized, controlled trial.
Batail, Jean-Marie; Xiao, Xiaoqian; Azeez, Azeezat; Tischler, Claudia; Kratter, Ian H; Bishop, James H; Saggar, Manish; Williams, Nolan R.
Afiliação
  • Batail JM; Stanford Brain Stimulation Lab, Stanford, CA, USA.
  • Xiao X; Pôle Hospitalo-Universitaire de Psychiatrie Adulte, Centre Hospitalier Guillaume Régnier, Rennes, France.
  • Azeez A; Stanford Brain Stimulation Lab, Stanford, CA, USA.
  • Tischler C; Stanford Brain Stimulation Lab, Stanford, CA, USA.
  • Kratter IH; Baylor College of Medicine, Houston, TX, USA.
  • Bishop JH; Stanford Brain Stimulation Lab, Stanford, CA, USA.
  • Saggar M; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.
  • Williams NR; Stanford Brain Stimulation Lab, Stanford, CA, USA.
Transl Psychiatry ; 13(1): 240, 2023 07 03.
Article em En | MEDLINE | ID: mdl-37400432
ABSTRACT
Here, we investigated the brain functional connectivity (FC) changes following a novel accelerated theta burst stimulation protocol known as Stanford Neuromodulation Therapy (SNT) which demonstrated significant antidepressant efficacy in treatment-resistant depression (TRD). In a sample of 24 patients (12 active and 12 sham), active stimulation was associated with significant pre- and post-treatment modulation of three FC pairs, involving the default mode network (DMN), amygdala, salience network (SN) and striatum. The most robust finding was the SNT effect on amygdala-DMN FC (group*time interaction F(1,22) = 14.89, p < 0.001). This FC change correlated with improvement in depressive symptoms (rho (Spearman) = -0.45, df = 22, p = 0.026). The post-treatment FC pattern showed a change in the direction of the healthy control group and was sustained at the one-month follow-up. These results are consistent with amygdala-DMN connectivity dysfunction as an underlying mechanism of TRD and bring us closer to the goal of developing imaging biomarkers for TMS treatment optimization.Trial registration ClinicalTrials.gov NCT03068715.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Transtorno Depressivo Maior / Transtorno Depressivo Resistente a Tratamento Tipo de estudo: Clinical_trials / Guideline Limite: Humans Idioma: En Revista: Transl Psychiatry Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Transtorno Depressivo Maior / Transtorno Depressivo Resistente a Tratamento Tipo de estudo: Clinical_trials / Guideline Limite: Humans Idioma: En Revista: Transl Psychiatry Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos